| 摘要 |
<p>Disclosed are compounds of Formula (I): and the pharmaceutically acceptable salts thereof, wherein "A" is S-; -SO-, -SO2-, -O- or NRac-, wherein Rac is H, or C1-20 alkyl and R1 through R5 are defined herein. Also disclosed are pharmaceutical formulations comprising a compound of Formula I and methods of treating, managing, or ameliorating diseases amenable to treatment, management, or amelioration by inhibition of LRRK2 kinase activity, for example, Parkinson's disease.</p> |
| 申请人 |
MERCK SHARP & DOHME CORP.;MCCAULEY, JOHN, A.;RAJAPAKSE, HEMAKA, A.;GRESHOCK, THOMAS, J.;SANDERS, JOHN;KIM, BOYOUNG;RADA, VANESSA, L.;KERN, JONATHAN, T.;STEVENSON, HEATHER, H.;BILODEAU, MARK, T. |
发明人 |
MCCAULEY, JOHN, A.;RAJAPAKSE, HEMAKA, A.;GRESHOCK, THOMAS, J.;SANDERS, JOHN;KIM, BOYOUNG;RADA, VANESSA, L.;KERN, JONATHAN, T.;STEVENSON, HEATHER, H.;BILODEAU, MARK, T. |
